Tıp Fakültesi / Faculty of Medicine

Permanent URI for this collectionhttps://hdl.handle.net/11727/1403

Browse

Filters

2014 - 201952020 - 20231

Settings

Author: search.filters.author.Aydin, Mehtapsearch.filters.applied.f.publicationcategory: search.filters.publicationcategory.Makale - Ulusal Hakemli Dergi

Search Results

Now showing 1 - 6 of 6
  • No Thumbnail Available
    Item
    The Turkish Clinical Microbiology and Infectious Diseases Society (KLIMIK) Evidence-Based Guideline for the Diagnosis and Treatment of Brucellosis, 2023
    (2023) Simsek-Yavuz, Serap; Ozger, Selcuk; Benli, Aysun; Ates, Can; Aydin, Mehtap; Aygun, Gokhan; Azap, Alpay; Azap, Ozlem; Basaran, Seniha; Demirturk, Nese; Ergonul, Onder; Kocagul-Celikbas, Aysel; Kuscu, Ferit; Saricaoglu, Elif Mukime; Sayin-Kutlu, Selda; Turker, Nesrin; Turkoglu-Yilmaz, Emine
    Although brucellosis is very common in the world and Turkiye, there are no evidence-based guidelines to guide the diagnosis and treatment of the disease. This guide has been prepared by the Turkish Society of Clinical Microbiology and Infectious Diseases to provide evidence-based recommendations to physicians from different specialties interested in the diagnosis and treatment of brucellosis. The recommendations of the Clinical Practice Guide Development Guide of the Infectious Diseases Society of America (IDSA) were taken as the basis for preparing this guide. The guideline preparation group determined 20 questions considered to be important in the diagnosis and treatment of brucellosis, and the publications that could answer these questions prepared in PICO (Population/Patient [P], Intervention [I], Comparison [C], Outcome [O]) format, were searched in ULAKBIM Tr Dizin, PubMed, Cochrane databases without date restrictions. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) Working Group method was used to rank the evidence and determine the strength of the recommendations for each PICO question and for each individual outcome. Meta-analyses of comparative clinical studies were performed to answer the PICO questions. Individual participant data (IPD) meta-analyses with data obtained from case reports and case series were conducted in the absence of comparative clinical studies. It is planned to update the recommendations at regular intervals in line with the results of new studies.
  • No Thumbnail Available
    Item
    Comparison of Haematologic Side Effects of Different Pegylated Interferon-α Molecules Combined With Ribavirin
    (2014) Aydin, Mehtap; Aksoz, Elif; Korkut, Oguzhan; Akhan, Sila; https://orcid.org/0000-0003-4044-9366; HLX-0937-2023
    Objective: Treatment of chronic hepatitis C virus (HCV) infection with pegylated interferon (PegIFN) and ribavirin causes haematological side effects such as anemia, neutropenia and trombocytopenia. This study aimed to evaluate and compare the haematological side effects of PegIFN alpha-2a and PegIFN alpha-2b with ribavirin in the treatment of chronic HCV infection. Methods: 103 patients treated with PegIFN alpha-2b plus ribavirin and 70 patients treated with PegIFN alpha-2a plus ribavirin were included in this retrospective study. Patients' haematological parameters in first and third month's visits were compared with pretreatment test results. Results: In all patients, 21.2% had anemia (haemoglobin <10 g/dL), 3.8% had neutropenia (<750/mm(3)) and 6.2% had thrombocytopenia (<75x10(9)/L) at the end of the third month. When compared with initial levels, significant decreases in haemoglobin, neutrophil and thrombocyte counts were observed at first and third months in both groups. There wasn't a significant decrease in thrombocyte counts in the first month between two groups, however, a more significant decrease in thrombocyte counts were observed in patients who received PegIFN alpha-2a plus ribavirin than the patients receiving PegIFN alpha-2b plus ribavirin during the third month. Conclusions: PegIFN alpha-2b seems to have similar haematologic side effects, compared with PegIFN alpha-2a except the effects on the thrombocyte counts during the third month.
  • No Thumbnail Available
    Item
    Management of Chronic Hepatitis in Special Hosts and Special Situations: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases
    (2014) Mistik, Resit; Aydin, Mehtap; Aksoy, Suleyman; Altin, Nilgun; Altunal, Nilsun; Avsar, Kemal; Bezirgan, Selma; Buke, Cagri; Celik, Ali Kutta; Celik, Ekrem; Dikici, Nebahat; Hizel, Kenan; Iskender, Serap; Kaya, Ali; Korkmaz, Fatime; Kose, Sukran; Sacligil, Cahide; Sirmatel, Fatma; Tarakci, Huseyin; Turgut, Huseyin; Tutuncu, Ediz; Yulugkural, Zerrin; https://orcid.org/0000-0003-4044-9366; HLX-0937-2023
    Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases convened a meeting to develop a consensus report on management of chronic hepatitis in special hosts and special situations. Relevant literature and international guidelines were reviewed, and recommendations agreed are presented at the end of each section such as therapy of chronic hepatitis B (CHB) in patients with compensated and decompensated cirrhosis, prevention and therapy of recurrent hepatitis B after liver transplantation, management of fulminant hepatitis B, therapy of CHB in hemodialysis patients, management of CHB in nonliver solid organ transplant recipients, management of CHB in immunosuppressed nontransplant patients, therapy of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) coinfection, management of HBV and hepatitis C virus (HCV) coinfection, management of CHB in alcoholic patients and injecting drug users, therapy of CHB in pregnancy and lactation period, extrahepatic manifestations in HBV infection, HBV, HCV and hepatitis D virus coinfection, therapy of chronic hepatitis C (CHC) in patients with compensated and decompensated cirrhosis, treatment of patients with recurrent HCV infection following liver transplantation, therapy of CHC in hemodialysis patients, management of CHC in nonliver solid organ transplant recipients, therapy of HCV, HBV and HIV coinfection, management of CHC in immunosuppressed nontransplant patients, HCV infection and biological agents, HCV infection and chemotherapy, management of CHC in alcoholic patients and injecting drug users, fatty liver and CHC, hemoglobinopathy and CHC, CHC in pregnancy and lactation period, extrahepatic manifestations in HCV infection.
  • No Thumbnail Available
    Item
  • No Thumbnail Available
    Item
    Wegener Granulomatosis Complicated by Brain Abscess Caused by Nocardia spp.
    (2016) Sahin, Sevgi; Balcan, Baran; Kiziltas, Safak; Aydin, Mehtap; Y-1366-2018; A-4721-2018
    Wegener granulomatosis is a multisystemic disease associated with high mortality rate and characterized by necrotizing granulomatous vasculitis predominantly in the respiratory tract and kidneys. Presence of kidney failure at the time of diagnosis describes a poor prognostic marker. We presented a Wegener granulomatosis case complicated with brain abscess caused by Nocardia.
  • Thumbnail Image
    Item
    Bloodstream Infections: Etiologic Agents and Their Antibiotic Resistance Rates
    (2016) Aydin, Mehtap; Kasikcioglu, Cemre; Nargiz-Kosucu, Sibel; Timurkaynak, Funda; Arslan, Hande; 0000-0002-5708-7915; ABG-7034-2021
    Objective: In this study, we aimed to investigate the etiological agents of bloodstream infections (BSIs) and their antibiotic resistance rates. Methods: The rates of antibiotic resistance of the microorganisms isolated from blood cultures in the microbiology laboratory between 2012 and 2013 were evaluated retrospectively. Blood cultures were performed by using BACTEC (TM) 9120 (Becton Dickinson, Sparks, MD, USA) automated system. Microorganisms that were isolated were identified by routine microbiological methods. Results: In our study, BSIs were most frequently detected in the cardiovascular surgery clinic. Out of 95 bacteria isolated from blood culture, 61 (64.2) were Gram-negative bacteria (46% enteric, 18% nonfermentative), 20 (21%) were Candida spp. and 14 (15%) were Gram-positive bacteria. The most effective antibiotics for enteric bacteria were found as colistin, followed by imipenem, meropenem and amikacin and for nonfermentative Gram-negative bacteria as colistin, cefepime, piperacillin-tazobactam, imipenem and amikacin. Conclusions: When the resistance rates were compared within two years, significant increases in resistance were observed for quinolones and ceftazidime in nonfermentative bacteria, and for carbapenems in enteric bacteria. Regular monitoring of etiological agents of BSIs and their antibiotic resistance rates will guide the selection of empiric therapy.